Thelansis

Psoriatic Arthritis (PsA) Market Outlook Thelansis’s “Psoriatic Arthritis (PsA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Psoriatic Arthritis (PsA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s ...

Psoriatic Arthritis (PsA) Market Outlook Thelansis’s “Psoriatic Arthritis (PsA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Psoriatic Arthritis (PsA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Psoriatic Arthritis (PsA) Overview Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory condition primarily affecting the joints and the areas where tendons and ligaments connect to bones. It typically co-occurs with a skin condition known as psoriasis. Enthesitis is among its most common distinguishing features. Other clinical manifestations include joint swelling, painful and itchy red patches, and the accumulation o...

 Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory condition primarily affecting the joints and the areas where tendons and ligaments connect to bones. It typically co-occurs with a skin condition known as psoriasis. Enthesitis is among its most common distinguishing features. Other clinical manifestations include joint swelling, painful and itchy red patches, and the accumulation of silvery dead skin cells. PsA can also impact the sacroiliac joint of the pelvic region and the spine, resulting in stiffness in the neck and back. The precise cause of psoriatic arthritis remains unknown. It usually emerges in individuals between 30 and 50, although it can begin as early as childhood. Both genders are equally susceptible to PsA, and its genetic epidemiology sets it apart. PsA has been linked to human leukocyte antigen (HLA) class 1 allele, compared to rheumatoid arthritis (RA), associated with HLA class 2 alleles. Notably, PsA presents distinct extra-articular manifestatio...